Cytomegalovirus Infections
Also known as: CMV, Cytomegalovirus, Herpesvirus, Opportunistic?
Methodology & AI Transparency ⓘ
Cytomegalovirus Infections Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cytomegalovirus (CMV) is a virus found around the world.
- 2 Real-world patient consensus: Synonyms for Cytomegalovirus Infections (B25.9): CMV, Cytomegalovirus, Herpesvirus (Infections & Antivirals).
- 3 Typical cash cost range: Differential triage of Cytomegalovirus Infections (B25.9) utilizes antimicrobial stewardship (narrow-spectrum in Cytomegalovirus Infections (B25.9: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Longitudinal Cytomegalovirus Infections monitoring tracks C-Reactive Protein / in Cytomegalovirus Infections (B25.9: Procalcitonin) toward Resolution to baseline (B25.9).
Ask our AI Specialists anything about Cytomegalovirus Infections
What Is Cytomegalovirus Infections?
Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50% and 80% of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems.
Pathophysiology, Underlying Causes & Clinical Presentation
In Cytomegalovirus Infections (B25.9), physiological disruption stems from microbial (bacterial [Cytomegalovirus Infections B25.9], Cross-referenced with NIH MeSH (Cytomegalovirus Infections), informing Bacterial, Viral & Fungal Infections protocols that track Targeted PCR / in Cytomegalovirus Infections (B25.9: Culture & Sensitivity) (Pathogen clearance / negative test (B25.9)).
Common Symptoms & Clinical Signs
- • Presentation of Cytomegalovirus Infections (B25.9): acute fever, chills, in Cytomegalovirus Infections (B25.9: malaise, and myalgias)
- • Secondary Cytomegalovirus Infections clinical sign: sore throat, productive in Cytomegalovirus Infections (B25.9: cough, sinus/ear pain,)
- • Symptom flares in Cytomegalovirus Infections correlating with C-Reactive Protein / in Cytomegalovirus Infections (B25.9: Procalcitonin) deviation outside Resolution to baseline (B25.9)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Cytomegalovirus Infections (B25.9: pathogen-directed duration) or) evaluation (B25.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cytomegalovirus Infections Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B25.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: C-Reactive Protein / in Cytomegalovirus Infections (B25.9: Procalcitonin) | Resolution to baseline (B25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Cytomegalovirus Infections (B25.9: Culture & Sensitivity) | Pathogen clearance / negative test (B25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Cytomegalovirus Infections (B25.9: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B25.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cytomegalovirus Infections
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Valganciclovir Valcyte • RxCUI 863559 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | 89% | $1.8415 | $ 39.16 /mo |
| Prevymis (Letermovir) Prevymis • RxCUI RXN-B00063076 | Cytomegalovirus DNA Terminase Complex Inhibitor | 80% | $2.1500 | $ 163.30 /mo |
| Letermovir Prevymis • RxCUI RXN-00063076-2321 | Cytomegalovirus DNA Terminase Complex Inhibitor | 93% | $0.3800 | $ 23.89 /mo |
| Livtencity (Maribavir) Livtencity • RxCUI RXN-B64764800 | Cytomegalovirus pUL97 Kinase Inhibitor | 93% | $1.2300 | $ 97.06 /mo |
| Zirgan (Ganciclovir) Zirgan • RxCUI 864650 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | 88% | $91.2378 | $ 640.00 /mo |
| Valcyte (Valganciclovir) Valcyte • RxCUI 313566-B61269480 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | 78% | $2.1751 | $ 39.16 /mo |
| Ganciclovir Sodium Ganciclovir Sodium Generic • RxCUI 1999531 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | 79% | $1.2600 | $ 59.53 /mo |
| Cidofovir Dihydrate Cidofovir Dihydrate Generic • RxCUI RXN-23155216-2629 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | 77% | $0.7400 | $ 38.47 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cytomegalovirus Infections)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides This analysis provides further evidence of RBL real-world benefits and safety across subgroups, including those at high risk for rCDI. Journal of clinical gastroenterology • 2024-09-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38019088 ↗ |
| Can This Approach Help? Inside the Latest Research on [Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on Further, the incidence of neutropenia during the treatment observation period was lower in the maribavir arm than in the valganciclovir arm (22.2% vs 55.6% ). Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi • 2025-12-14 • Phase III Randomized Trial | N = 18 | 88/100 | PMID 41486656 ↗ |
| Can This Approach Help? Inside the Latest Research on Kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease Kidney function did not impact staying on track with medication, quantifiable CMV DNAemia, or prophylaxis discontinuation in the letermovir group; however, staying on track with medication was lower, and quantifiable CMV... American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40701254 ↗ |
| New Insights on A prospective, randomized, parallel, active controlled, phase III Indian study of: What a 346-Participant Study Found Side effects (AEs) were similar for both vaccines, including pain at the injection site, skin redness, swelling, and pyrexia. Human vaccines & immunotherapeutics • 2024-12-31 • Phase III Randomized Trial | N = 346 | 87/100 | PMID 39445787 ↗ |
| New Insights on Maribavir for refractory cytomegalovirus infection (with or without resistance): What a 211-Participant Study Found Consistent with findings in the overall SOLSTICE population, this subgroup analysis of SOT recipients demonstrated greater effectiveness of maribavir for cytomegalovirus viremia. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • 2025-06-15 • Phase III Randomized Trial | N = 211 | 82/100 | PMID 39613120 ↗ |
Cytomegalovirus Infections Patient Community & “People Like Me” Threads
Filter Cytomegalovirus Infections community threads and patient logs by age, biological sex, dosage, and treatment duration.